We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Eurofins MWG Operon Joins Roche NimbleGen’s Certified Service Provider Program

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Roche NimbleGen has announced that Eurofins MWG Operon, an Ebersberg, Germany-based company, has officially become a Certified Service Provider (CSP) for NimbleGen Sequence Capture. They will provide services for NimbleGen Titanium Optimized Sequence Capture coupled with sequencing services from 454 Life Sciences, a Roche Company.

Eurofins MWG Operon has passed a rigorous certification test plan to achieve precise experimental standards to officially become part of the Roche NimbleGen Certified Service Provider Program. Their certification marks the first genomic service provider to join the global Roche NimbleGen CSP Program in Europe. They will process customer gDNA samples for genomic enrichment using the complete NimbleGen Sequence Capture workflow optimized for 454 Titanium sequencing using 385K Arrays.

"The Sequence Capture technology of Roche NimbleGen is a perfect fit to our next-generation sequencing platform," said Bruno Poddevin, Ph.D., Head of Eurofins Genomic Services, “and contributes significant speed and an optimized workflow to support our position as a leading provider of state-of the art services to our customers.”

“Roche NimbleGen welcomes Eurofins MWG Operon as our first European certified service provider for our innovative Sequence Capture technology. We anticipate that our relationship with Eurofins MWG Operon will result in significant growth for the targeted resequencing market and will serve as a model CSP to further expand our service channels on a country, regional, and global level," said Dr. Gerd Maass, CEO of Roche NimbleGen, Inc.